```html

Kite‑type Pulmonary Embolism – Comprehensive Medical Guide

Overview

Kite‑type pulmonary embolism (PE) is a radiologic pattern of acute PE in which a large, triangular or kite‑shaped clot occupies the proximal part of the main pulmonary artery or its primary branches. The name derives from the “kite” silhouette seen on contrast‑enhanced CT pulmonary angiography (CTPA). Although the term is primarily used by radiologists, it signals a high‑risk clot burden that can rapidly impair right‑ventricular (RV) function.

**Who it affects** – Like other forms of PE, kite‑type PE can occur in anyone, but it is most common in:

• Adults > 50 years old
• Patients with recent surgery, trauma, or prolonged immobilization
• Individuals with active cancer, especially those receiving chemotherapy
• People with inherited or acquired thrombophilia

**Prevalence** – Acute PE overall affects about 60–70 per 100,000 persons each year in the United States (CDC, 2023). Kite‑type PE represents roughly 10‑15 % of all diagnosed PEs, but it accounts for a disproportionate share of severe presentations and early mortality.<sup>1</sup>

Symptoms

Symptoms of kite‑type PE mirror those of other massive or sub‑massive emboli, but they tend to be more abrupt and severe because a large central clot sharply raises pulmonary artery pressure.

Cardiopulmonary

• Sudden dyspnea – rapid onset of shortness of breath, often described as “can’t catch my breath.”
• Chest pain – pleuritic (sharp, worsens with inspiration) or pressure‑like; may radiate to the left arm or jaw.
• Rapid heart rate (tachycardia) – >100 bpm; can be accompanied by palpitations.
• Hypotension – systolic BP < 90 mm Hg or a drop >40 mm Hg from baseline, indicating hemodynamic compromise.
• Syncope or presyncope – fainting or near‑fainting episodes due to reduced cardiac output.
• Respiratory alkalosis – rapid breathing lowering CO₂, detectable on arterial blood gas.

Systemic

• Fever – low‑grade (often <38.5 °C), can mimic infection.
• Leg swelling or pain – suggests the clot originated from a deep vein thrombosis (DVT).
• Cough or hemoptysis – cough may produce blood‑tinged sputum if pulmonary infarction occurs.
• Fatigue, anxiety, sense of impending doom – common in acute high‑stress events.

Causes and Risk Factors

PE results from a thrombus that dislodges (embolizes) from a peripheral vein—most often the deep veins of the legs or pelvis—and travels to the pulmonary arterial circulation. The “kite” shape arises when the clot is large enough to occupy the main trunk or the first bifurcation, creating a central, triangular density on imaging.

Primary Causes

• Venous stasis – prolonged immobilization (post‑operative, long‑haul flights, wheelchair dependency).
• Endothelial injury – surgery, trauma, central venous catheter placement.
• Hypercoagulability – inherited disorders (Factor V Leiden, prothrombin G20210A), malignancy, antiphospholipid syndrome, hormonal therapy.

Key Risk Factors

• Age > 60 years
• Obesity (BMI ≥ 30 kg/m²)
• Active cancer (especially lung, pancreatic, ovarian, and brain tumors)
• Recent major surgery (especially orthopedic or abdominal)
• Pregnancy and the postpartum period
• Use of estrogen‑containing medications (oral contraceptives, hormone replacement therapy)
• Chronic inflammatory diseases (e.g., inflammatory bowel disease, rheumatoid arthritis)
• Inherited thrombophilia

Having multiple risk factors dramatically raises the likelihood of a large, central embolus that can appear as a kite on imaging.

Diagnosis

Prompt recognition is crucial because kite‑type PE carries a high early‑mortality risk. Diagnosis combines clinical assessment, risk‑scoring tools, laboratory tests, and imaging.

Clinical Assessment

• History and physical exam focusing on dyspnea, chest pain, leg signs, and hemodynamics.
• Use of validated scores such as the Wells or PERC criteria to estimate pre‑test probability.

Laboratory Tests

• D‑dimer – highly sensitive but not specific; a normal level effectively rules out PE in low‑risk patients.
• Arterial blood gas – may show hypoxemia and respiratory alkalosis.
• Cardiac biomarkers (troponin, BNP) – elevated levels suggest RV strain and help risk‑stratify.
• Complete blood count, renal function, and coagulation profile to guide therapy.

Imaging – The Cornerstone

• CT Pulmonary Angiography (CTPA) – First‑line test; the kite‑type pattern appears as a large, centrally located filling defect with a triangular outline extending from the main pulmonary artery into its primary branches.
• Ventilation‑Perfusion (V/Q) Scan – Used when CTPA is contraindicated (e.g., severe contrast allergy, renal failure). A “high‑probability” scan can infer a central embolus.
• Compression Ultrasound of the Legs – Detects DVT, supporting the diagnosis of PE.
• Echocardiography (transthoracic or transesophageal) – Evaluates RV size/function; signs of pressure overload are common in kite‑type PE.
• Chest X‑ray – Typically nonspecific but may show Westermark sign or pleural effusion.

Risk Stratification

After confirmation, patients are classified as:

• Massive (high‑risk) – Sustained hypotension, shock, or cardiac arrest.
• Sub‑massive (intermediate‑risk) – Normal blood pressure but evidence of RV dysfunction or myocardial injury.
• Low‑risk – Stable hemodynamics and no RV strain.

Kite‑type PE most often falls into the massive or sub‑massive categories, prompting aggressive therapy.

Treatment Options

Treatment goals are to restore pulmonary perfusion, prevent clot propagation, and mitigate the risk of recurrence. Management is individualized based on hemodynamic status, comorbidities, and bleeding risk.

Initial Stabilization

• Supplemental oxygen to maintain SpO₂ ≥ 94 %.
• IV access with fluid resuscitation if hypotensive (cautiously, to avoid RV overload).
• Continuous cardiac monitoring and frequent vitals.

Anticoagulation

• Rapid‑acting agents – Intravenous unfractionated heparin (UFH) or low‑molecular‑weight heparin (LMWH) bolus, then infusion; UFH preferred when immediate reversal may be needed.
• Transition – To oral anticoagulants (warfarin, direct oral anticoagulants – DOACs such as apixaban, rivaroxaban) after stabilization, typically for a minimum of 3 months.

Thrombolytic Therapy

Indicated for massive or deteriorating sub‑massive kite‑type PE.

• Systemic alteplase 100 mg over 2 hours (or weight‑adjusted regimens).
• Contraindications include recent intracranial surgery, active bleeding, or uncontrolled hypertension.
• Catheter‑directed thrombolysis (CDT) may be used to deliver lower doses locally, reducing bleeding risk.

Mechanical Interventions

• Catheter‑based thrombectomy – Emerging technology (e.g., FlowTriever, AngioVac) that physically removes clot; useful when thrombolysis is contraindicated.
• Surgical embolectomy – Reserved for patients in cardiac arrest or when percutaneous options fail.

Supportive Measures

• Vasopressors (norepinephrine) for refractory hypotension.
• Inotropes (dobutamine) if RV failure persists.
• Mechanical ventilation only if respiratory failure develops.

Lifestyle & Long‑Term Medications

• Continuation of anticoagulation for 3–6 months (or indefinitely if unprovoked or high‑risk).
• Compression stockings for DVT prophylaxis.
• Smoking cessation, weight management, and regular physical activity.

Living with Kite‑type Pulmonary Embolism

Survivors often face challenges related to medication management, activity restrictions, and anxiety about recurrence.

Medication Adherence

• Set daily alarms or use pill‑organizer apps.
• Know the signs of over‑anticoagulation (e.g., easy bruising, nosebleeds) and under‑anticoagulation (new leg swelling).
• Schedule regular INR checks if on warfarin; DOACs require less monitoring but still need yearly renal function tests.

Physical Activity

• Begin with gentle walking; aim for at least 150 min of moderate‑intensity activity per week as tolerated.
• Avoid prolonged immobilization—stand or walk for 5‑10 minutes every hour during long trips.
• Discuss with your physician before starting high‑intensity sports or heavy lifting.

Follow‑up Care

• First follow‑up appointment within 1–2 weeks after discharge for symptom review and medication adjustment.
• Repeat imaging (CTPA or V/Q) is not routinely required unless symptoms persist or worsen.
• Consider a referral to a thrombosis clinic for specialized counseling.

Emotional Well‑being

• Experiencing a massive PE can be traumatic; seeking counseling or support groups (e.g., Pulmonary Embolism Society) is beneficial.
• Mind‑body techniques—deep breathing, progressive muscle relaxation—can reduce anxiety.

Prevention

Primary prevention focuses on mitigating the three components of Virchow’s triad (stasis, hypercoagulability, endothelial injury).

General Measures

• Maintain a healthy weight (BMI < 25 kg/m²).
• Engage in regular aerobic exercise (minimum 30 min most days).
• Quit smoking; use nicotine‑replacement or prescription aids if needed.
• Stay hydrated, especially during long flights or hospitalization.

Medical Prophylaxis

• Low‑dose LMWH, low‑dose unfractionated heparin, or intermittent pneumatic compression devices for hospitalized patients at risk.
• Extended prophylaxis (e.g., apixaban 2.5 mg BID) for up to 35 days after major orthopedic surgery, per American College of Chest Physicians (ACCP) guidelines.

Special Situations

• Pregnancy – LMWH is safe; compression stockings during antenatal visits.
• Cancer – Direct oral anticoagulants (rivaroxaban, edoxaban) are now FDA‑approved for cancer‑associated thrombosis, but discuss with oncology.
• Genetic thrombophilia – Family screening and lifelong anticoagulation may be recommended.

Complications

If left untreated or inadequately treated, kite‑type PE can lead to serious, sometimes fatal complications.

• Cardiac arrest – Acute RV failure precipitates sudden circulatory collapse.
• Chronic thromboembolic pulmonary hypertension (CTEPH) – Persistent obstruction leads to progressive pulmonary hypertension and right‑heart failure.
• Recurrent PE – Risk is highest within the first 3 months after the initial event.
• Pulmonary infarction – Pleural‑based necrosis causing persistent chest pain and hemoptysis.
• Bleeding complications – From anticoagulation or thrombolysis; intracranial hemorrhage is the most feared.

When to Seek Emergency Care

References

1. Moores LK, et al. "Guidelines for the Diagnosis and Management of Acute Pulmonary Embolism." Chest. 2020;158(3):e112–e120. DOI:10.1016/j.chest.2020.04.012.
2. Mayo Clinic. “Pulmonary embolism.” Updated 2023. https://www.mayoclinic.org
3. CDC. “Pulmonary embolism (PE) data and statistics.” 2023. https://www.cdc.gov
4. American College of Chest Physicians. “Antithrombotic Therapy for VTE Disease.” ACCP Evidence‑Based Clinical Practice Guidelines, 2023.
5. World Health Organization. “Global Health Estimates, 2022: Mortality and burden of disease.” WHO Press, 2023.

```